Prostate Cancer & BPHArchives
Embedding genetic testing in the metastatic prostate cancer pathway: understanding patient and physician perspectives
Prostate Cancer & BPH 1 min.
To understand how genetic (homologous recombination repair [HRR], including BReast CAncer [BRCA]) testing is being embedded in clinical practice and identify testing challenges given global approvals of poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) for metastatic prostate cancer (mPCa)....
Correlations of biochemical and clinical outcomes with 10-year results after robotic stereotactic body radiotherapy for localized prostate cancer
Prostate Cancer & BPH 4 min.
Prostate cancer is the second most common malignancy, after lung cancer, among men aged ≥ 65 years in Korea, with an age-specific incidence rate of 375.4 per 100,000 in 2020 [1]. Despite an increasing trend in incidence, prostate cancer carries one of the highest cancer survival rates, with a 5-year...
Diagnostic value of 18F-prostate-specific membrane antigen-1007 PET/MRI versus 18F-prostate-specific membrane antigen-1007 PET/computed tomography for biochemical recurrence of prostate cancer after radical prostatectomy.
Prostate Cancer & BPH 1 min.
To assess the diagnostic value of fluorine 18 (18F)-labeled prostate-specific membrane antigen (PSMA)-1007 PET/MRI and compare with that of 18F-PSMA-1007 PET/computed tomography (CT) for biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy. Materials and methods: We enrolled...
Efficacy and safety of urethral sparing versus other robot-assisted simple prostatectomy for large volume benign prostatic hyperplasia: a systematic review and meta-analysis
Prostate Cancer & BPH 5 min.
Benign prostatic hyperplasia (BPH) is a prevalent urological condition that predominantly affects older men [1]. Around 20% of males over the age of 50 encounter urinary difficulties, and its occurrence rises considerably with age, affecting over 50% of men by 70 years old [2]. The 2019 Global Burden...
Treatment options in hormone-sensitive prostate cancer: targeting the androgen-sensitive pathway
Prostate Cancer & BPH 1 min.
This podcast examines how hormone-sensitive prostate cancer (HSPC) is treated, specifically looking at therapies that target the androgen-sensitive pathway. Identification of patients and the clinical rationale for following different treatment...
